PainResearch Phase

Palmitoylethanolamide (PEA)

Oral

Overview

An endogenous fatty acid amide belonging to the N-acylethanolamine family, naturally produced by cells in response to tissue damage and inflammation. PEA acts primarily through peroxisome proliferator-activated receptor alpha (PPAR-alpha), downregulating mast cell activation and pro-inflammatory mediator release.

Mechanism of Action

It also modulates the endocannabinoid system via the entourage effect, enhancing anandamide activity at CB1/CB2 receptors and TRPV1 channels without directly binding cannabinoid receptors..

Research Summary & Key Findings

Meta-analysis of 12 clinical trials (>1,600 patients) demonstrated significant analgesic efficacy in chronic pain conditions including sciatic pain, neuropathy, and pelvic pain (Paladini et al., Pain Ther, 2016). Studied extensively for its anti-inflammatory and neuroprotective properties with a favorable safety profile. Available as a nutraceutical/food supplement in many countries. Not FDA-approved as a drug but classified as GRAS.

Clinical Status

Research Phase

Palmitoylethanolamide (PEA) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Oral

Related Peptides in Pain

Find a Provider

Find a verified provider who offers Palmitoylethanolamide (PEA) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Palmitoylethanolamide (PEA).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.